Table 2.
Variables | Baseline | 4-month follow-up | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Patient | Partner | Patient | Partner | |||||||||
N | Mean | SD | N | Mean | SD | N | Mean | SD | N | Mean | SD | |
Quality of life1 | 134 | 85.20 | 13.09 | 134 | 85.63 | 11.87 | 124 | 84.95 | 12.39 | 124 | 83.82 | 13.07 |
Social support1 | 134 | 88.18 | 12.12 | 134 | 85.24 | 14.25 | 124 | 86.69 | 13.13 | 124 | 84.52 | 15.12 |
Uncertainty2 | 134 | 60.54 | 15.53 | 134 | 61.84 | 16.05 | 124 | 60.31 | 17.16 | 124 | 62.90 | 16.91 |
Levels of dyadic communication1 | 130 | 3.72 | .66 | 132 | 3.70 | .63 | 120 | 3.63 | .73 | 122 | 3.51 | .78 |
Pca-specific symptoms_urine1 | 133 | 77.29 | 16.01 | 134 | 4.08 | 1.18 | 124 | 81.19 | 15.85 | 124 | 4.18 | 1.13 |
Pca-specific symptoms_bowel1 | 131 | 88.71 | 12.01 | 134 | 4.58 | .87 | 122 | 90.05 | 12.73 | 124 | 4.65 | .82 |
Pca-specific symptoms_sexual1 | 130 | 26.76 | 21.92 | 132 | 3.30 | 1.49 | 123 | 29.13 | 23.04 | 123 | 3.16 | 1.60 |
PCa-specific symptoms_hormonal1 | 134 | 82.16 | 15.01 | 134 | 4.08 | 1.19 | 124 | 83.09 | 15.13 | 124 | 4.07 | 1.27 |
General symptom score2 | 134 | 7.07 | 4.35 | 134 | 5.50 | 3.82 | 124 | 6.43 | 4.24 | 124 | 6.23 | 4.48 |
Variables | 8-month follow-up | 12-month follow-up | F ratio (df=3) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patient | Partner | Patient | Partner | Patient | Partner | |||||||||
N | Mean | SD | N | Mean | SD | N | Mean | SD | N | Mean | SD | Time Effect | Time Effect | |
Quality of life1 | 122 | 86.54 | 12.83 | 122 | 83.85 | 14.27 | 114 | 86.52 | 12.60 | 119 | 84.01 | 14.93 | .54 | .54 |
Social support1 | 122 | 86.99 | 12.02 | 122 | 83.98 | 14.41 | 114 | 87.34 | 13.50 | 119 | 84.10 | 16.05 | .34 | .19 |
Uncertainty2 | 122 | 58.78 | 14.91 | 121 | 61.66 | 16.98 | 114 | 57.08 | 15.62 | 114 | 59.95 | 16.69 | 1.23 | .63 |
Levels of dyadic communication1 | 119 | 3.73 | .64 | 120 | 3.50 | .73 | 111 | 3.64 | .68 | 116 | 3.45 | .76 | .77 | 2.93* |
Pca-specific symptoms_urine1 | 120 | 82.79 | 14.15 | 121 | 4.22 | 1.10 | 113 | 83.57 | 13.93 | 114 | 4.30 | 1.05 | 4.34** | .81 |
Pca-specific symptoms_bowel1 | 120 | 89.96 | 12.39 | 121 | 4.62 | .82 | 112 | 90.63 | 11.13 | 114 | 4.61 | .82 | .55 | .16 |
Pca-specific symptoms_sexual1 | 119 | 29.53 | 23.65 | 120 | 3.23 | 1.57 | 112 | 32.43 | 24.49 | 112 | 3.21 | 1.58 | 1.20 | .18 |
PCa-specific symptoms_hormo1 | 122 | 85.02 | 14.53 | 120 | 4.12 | 1.20 | 111 | 85.71 | 13.75 | 114 | 4.07 | 1.17 | 1.55 | .04 |
General symptom score2 | 122 | 6.30 | 4.55 | 122 | 6.19 | 4.31 | 114 | 5.82 | 4.08 | 119 | 6.04 | 4.55 | 1.76 | .81 |
Higher scores indicate more positive results: better QOL, more communication, more support from others, and less Pca-specific symptoms
Higher scores indicate more negative results: more uncertainty about the illness and more symptom distress such as fatigue, nausea, and difficulty sleeping
P < .05;
P < .001